logo, Nilogen Oncosystems

News

Presentations

A fresh approach to Immuno-oncology: ex vivo analysis of drug efficacy in fresh patient tumor tissue
Soner Altiok, M.D., Ph.D., Chief Scientific Officer, Nilogen Oncosystems
3rd Annual ICI Boston
03/14/2017 to 03/16/2017
Boston, MA, USA
A fresh approach to Immuno-oncology: ex vivo analysis of drug efficacy in fresh patient tumor tissue
Soner Altiok, M.D., Ph.D., Chief Scientific Officer, Nilogen Oncosystems
Phacilitate Leaders' Forum - Immunotherapy World
01/23/2017 to 01/25/2017
Miami, FL USA
Early and Emerging Company Quick-fire Presentation
Soner Altiok, M.D., Ph.D., Chief Scientific Officer, Nilogen Oncosystems
Rational Combinations 360° Meeting
06/23/2016 to 06/24/2016
New York City, NY, USA
Bavituximab Activates CD8+ TILs in a 3D ex vivo System of Lung Cancer Patient Derived Tumors With Negative PD-L1 Expression
International Association for the Study of Lung Cancer (IASLC) 16th World Conference on Lung Cancer
09/06/2015 to 09/09/2015
Denver, CO, USA
Bavituximab Activates CD8+ Tumor Infiltrating Lymphocytes in a 3D ex vivo System of Lung Cancer Patients
American Society of Clinical Oncology (ASCO) 2015 Annual Meeting
05/29/2015 to 06/02/2015
Chicago, IL, USA
Bavituximab Modulates Tumor Microenvironment and Activates CD8+ Tumor Infiltrating Lymphocytes in a Patient-Derived 3D ex vivo System of Lung Cancer
American Association for Cancer Research (AACR) 2015 Annual Meeting
04/18/2015 to 04/22/2015
Philadelphia, PA, USA

News

Nivolumab With, Without Ipilimumab Active in Previously Treated SCLC
Scott Antonia, M.D., Ph.D., Chief Medical Officer, Nilogen Oncosystems
Clinical Science Symposium “The View Beyond Single-Agent Checkpoint Blockade” at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
06/04/2016
Chicago, Illinois